SRR934985
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.501
- PROTEIN_SECRETION+0.438
- INTERFERON_ALPHA_RESPONSE+0.418
- NOTCH_SIGNALING+0.403
- INTERFERON_GAMMA_RESPONSE+0.383
- IL6_JAK_STAT3_SIGNALING+0.355
- TNFA_SIGNALING_VIA_NFKB+0.341
- OXIDATIVE_PHOSPHORYLATION+0.331
- MYC_TARGETS_V1+0.325
- ADIPOGENESIS+0.302
Top 10 suppressed
- KRAS_SIGNALING_DN-0.331
- CHOLESTEROL_HOMEOSTASIS-0.269
- HEDGEHOG_SIGNALING-0.243
- SPERMATOGENESIS-0.230
- APICAL_SURFACE-0.171
- PANCREAS_BETA_CELLS-0.135
- ESTROGEN_RESPONSE_EARLY-0.054
- APICAL_JUNCTION-0.046
- ESTROGEN_RESPONSE_LATE-0.036
- G2M_CHECKPOINT-0.033
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9ECB653A-A04F-457C-92FC-D13424511A47 | — | — | 0.870 |
| 2 | 165395C6-1028-49DF-B15D-4D8064D00995 | — | — | 0.865 |
| 3 | 8C34CD93-1AC0-4920-9E72-439EED0CF85D | — | — | 0.862 |
| 4 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.859 |
| 5 | 9041BE5E-3BC7-4495-9461-8FFA2CAEB524 | — | — | 0.858 |
| 6 | B583566B-A014-417A-A973-41204DC35ECF | — | — | 0.849 |
| 7 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.846 |
| 8 | R123 | — | — | 0.843 |
| 9 | 15FB165D-6751-4894-A904-C77EA723CFCB | — | — | 0.840 |
| 10 | SRR934885 | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.501 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.438 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.418 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.403 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.383 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.355 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.341 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.331 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.325 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.302 | Inavolisib | — uncovered |
| APOPTOSIS | 0.294 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.267 | Idelalisib | — uncovered |
| COMPLEMENT | 0.244 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.241 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.234 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.234 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.229 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.223 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.207 | Idelalisib | — uncovered |